donor regulatory t lymphocytes

Cell therapyexperimental

Clinical trial activity

6 trials · 12 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 2015 (NCT02385019)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetImmunity, passive

    Immunity, passive

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • donor regulatory t lymphocytes

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06052436Phase 1/Phase 2 (Phase 2)Jun 27, 2023Hospital General Universitario Gregorio Marañon, Universidad Carlos III Madrid
NCT04801563N/ASep 20, 2019University of Perugia
NCT03943238Phase 1Jun 1, 2019California Institute for Regenerative Medicine (CIRM), Northwestern University, Stanford University
NCT03101423N/AAug 1, 2016Guangxi Medical University, Hacettepe University
NCT02526329Phase 1Aug 1, 2015National Cancer Institute (NCI), Stanford University
NCT02385019Phase 1/Phase 2 (Phase 2)Mar 1, 2015Instituto de Medicina Molecular, instituto Portugues de Oncologia Porto, University of Lisbon
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (12)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Stanford UniversityAcademic/Hospital2212015
California Institute for Regenerative Medicine (CIRM)Academic/Hospital1012019
Guangxi Medical UniversityAcademic/Hospital1112016
Hacettepe UniversityAcademic/Hospital1012016
Hospital General Universitario Gregorio MarañonAcademic/Hospital1112023
Instituto de Medicina MolecularAcademic/Hospital1112015
instituto Portugues de Oncologia PortoAcademic/Hospital1012015
National Cancer Institute (NCI)Government1012015
Northwestern UniversityAcademic/Hospital1012019
Universidad Carlos III MadridAcademic/Hospital1012023
University of LisbonAcademic/Hospital1012015
University of PerugiaAcademic/Hospital1112019
12 organizations
Page 1 / 1